In recent times, Halberd Corporation (OTC:HALB) has been in the news at different times owing to the research that it commissioned in collaboration with Mississippi State University (MSU). This morning, the company came into the news cycle after it announced that it had decided to extend the original six-month research arrangement with the MSU by an extra couple of years.
The extra two years of research would involve projects that are yet to be defined. The decision had been reached by the company due to the high level of performance from MSU in the TBI Nasal Spray project at Halberd. In the news release from the company, it was also noted that the efficiency, professionalism, capabilities, and proficiency exhibited by the research team at MSU were also significant factors in the move.
Additionally, it was also noted in the news release that the scientific team at Halberd and the primary investigator, Dr. Russell Carr, had formed a strong interpersonal relationship. That had also influenced the decision by Halberd Corporation to extend the relationship. Dr. Carr spoke about the development as well. He stated that it had been a ‘gratifying experience’ for him to collaborate with the scientists at Halberd.
The Chief Technology Officer of Halberd Corporation, Mitchell S. Felder, who is a prolific inventor, also provided his thoughts about the development. He stated that the aim of the company’s collaboration with MSU was to get statistically significant inferences pertaining to its nasal spray meant for the treatment of cases of head trauma.
The Chief Executive Officer, Chairman, and President of the company, William A. Hartman, spoke about the extension of the arrangement with MSU as well. He stated that everyone at the company was highly satisfied with the efforts that had been delivered by the MSU staff, led by Dr. Carr. He went on to state that he was looking forward to the expanded scope of the research collaboration.